It will now be of great interest to further evaluate whether ADAM17‐mediated sIL‐6R shedding and ERK activation are restricted to mutant KRAS LAC or are also a driver event in other mutant KRAS cancers (e.g., colorectal and pancreatic). This evidence concerns the gene KRAS and cancer.